Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gail J Roboz

Showing results (51-60 of 201) with videos related to

Pageof 21
Sort By:
The Journal of Molecular Diagnostics : JMD|May 20, 2017
Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 MutationsNuria Mencia-Trinchant, Yang Hu, Maria Antonina Alas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid LeukemiaDaniel A Pollyea, John Barrett, Courtney D DiNardo, et al.
Leukemia & Lymphoma|October 25, 2022
Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndromeDavid C Helfgott, Sabrina Racine-Brzostek, Kelsey J Short, et al.
Leukemia & Lymphoma|June 27, 2009
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trialAzra Raza, Joseph G Jurcic, Gail J Roboz, et al.
Leukemia & Lymphoma|February 15, 2021
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndromeGail J Roboz, Pinkal Desai, Sangmin Lee, et al.
Cancer|October 6, 2018
Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutionsDavid P Steensma, Andrew M Brunner, Amy E DeZern, et al.
Leukemia Research|June 15, 2007
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasiaFrancis J Giles, Alan F List, Michael Carroll, et al.
Nature Biotechnology|January 8, 2020
The therapeutic landscape for cells engineered with chimeric antigen receptorsMatthew MacKay, Ebrahim Afshinnekoo, Jonathan Rub, et al.
British Journal of Haematology|December 12, 2025
Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia-related changes: Post hoc analysis of the QUAZAR AML-001 trialMaria Teresa Voso, Stéphane de Botton, Michael Pfeilstöcker, et al.
Cancer Medicine|December 22, 2020
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research ConsortiumRami S Komrokji, Najla H Al Ali, David Sallman, et al.
Pageof 21

Showing results (51-60 of 201) with videos related to

Sort By:
Pageof 21
The Journal of Molecular Diagnostics : JMD|May 20, 2017
Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 MutationsNuria Mencia-Trinchant, Yang Hu, Maria Antonina Alas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid LeukemiaDaniel A Pollyea, John Barrett, Courtney D DiNardo, et al.
Leukemia & Lymphoma|October 25, 2022
Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndromeDavid C Helfgott, Sabrina Racine-Brzostek, Kelsey J Short, et al.
Leukemia & Lymphoma|June 27, 2009
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trialAzra Raza, Joseph G Jurcic, Gail J Roboz, et al.
Leukemia & Lymphoma|February 15, 2021
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndromeGail J Roboz, Pinkal Desai, Sangmin Lee, et al.
Cancer|October 6, 2018
Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutionsDavid P Steensma, Andrew M Brunner, Amy E DeZern, et al.
Leukemia Research|June 15, 2007
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasiaFrancis J Giles, Alan F List, Michael Carroll, et al.
Nature Biotechnology|January 8, 2020
The therapeutic landscape for cells engineered with chimeric antigen receptorsMatthew MacKay, Ebrahim Afshinnekoo, Jonathan Rub, et al.
British Journal of Haematology|December 12, 2025
Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia-related changes: Post hoc analysis of the QUAZAR AML-001 trialMaria Teresa Voso, Stéphane de Botton, Michael Pfeilstöcker, et al.
Cancer Medicine|December 22, 2020
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research ConsortiumRami S Komrokji, Najla H Al Ali, David Sallman, et al.
Pageof 21